This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
by Ahan Chakraborty
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
by Kinjel Shah
PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Novo Nordisk (NVO) reached $69.82 at the closing of the latest trading day, reflecting a +1.16% change compared to its last close.
Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is It Too Late to Buy NVIDIA?
by Derek Lewis
At the forefront of the AI frenzy has been beloved NVIDIA, which has seen unprecedented growth over recent years. But if you've missed the run, is it too late to get in now?
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
by Ahan Chakraborty
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
by Kinjel Shah
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
by Kinjel Shah
ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
by Zacks Equity Research
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
by Ahan Chakraborty
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
by Zacks Equity Research
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
by Ahan Chakraborty
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
Will CVS Health's Formulary Move Boost Its Weight Management Program?
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) concluded the recent trading session at $69.72, signifying a -5.49% move from its prior day's close.
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?
by Ethan Feller
Hims & Hers stock crashes 30% on Monday after news of Novo Nordisk ending their partnership. Is HIMS now a compelling stock to buy?
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
by Zacks Equity Research
Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.
Bulls Shrug Off Iran Strikes, Recover from Initial Oil Jolt
by Andrew Rocco
Price action is the best 'tell' that exists on Wall Street. The resilient price action in the stock market suggests that geopolitical fears are likely overdone.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
by Kinjel Shah
LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
by Ahan Chakraborty
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
by Ahan Chakraborty
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.